{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:43:48Z","timestamp":1790909028452,"version":"4.1.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"DOI":"10.1093\/jac\/dki240","type":"journal-article","created":{"date-parts":[[2005,7,8]],"date-time":"2005-07-08T20:14:01Z","timestamp":1120853641000},"page":"277-281","source":"Crossref","is-referenced-by-count":88,"title":["Epstein\u2013Barr virus infections: prospects for treatment"],"prefix":"10.1093","volume":"56","author":[{"given":"Edward","family":"Gershburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Pagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,7,8]]},"reference":[{"key":"key\n\t\t\t\t20171010200240_B1","unstructured":"Pagano JS. Epstein-Barr Virus and the Infectious Mononucleosis Syndrome. In: Humes HD, Dupont HL, eds. Kelley's Textbook of Internal Medicine, 4th edn. Philadelphia: Lippincott-Raven Publishers, 2000; 2181\u20135."},{"key":"key\n\t\t\t\t20171010200240_B2","doi-asserted-by":"crossref","unstructured":"Elion GB. The chemotherapeutic exploitation of virus-specified enzymes. Adv Enzyme Reg1980; 18,53\u201366.","DOI":"10.1016\/0065-2571(80)90008-4"},{"key":"key\n\t\t\t\t20171010200240_B3","doi-asserted-by":"crossref","unstructured":"Colby BM, Shaw JE, Elion GB et al. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol1980; 34:560\u20138.","DOI":"10.1128\/JVI.34.2.560-568.1980"},{"key":"key\n\t\t\t\t20171010200240_B4","doi-asserted-by":"crossref","unstructured":"Colby BM, Furman PA, Shaw JE et al. Phosphorylation of acyclovir [9-(2-hydroxyethoxymethyl)guanine] in Epstein-Barr virus-infected lymphoblastoid cell lines. J Virol1981; 38:606\u201311.","DOI":"10.1128\/JVI.38.2.606-611.1981"},{"key":"key\n\t\t\t\t20171010200240_B5","doi-asserted-by":"crossref","unstructured":"St Clair MH, Furman PA, Lubbers CM et al. Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir. Antimicrob Agents Chemother1980; 18:741\u20135.","DOI":"10.1128\/AAC.18.5.741"},{"key":"key\n\t\t\t\t20171010200240_B6","doi-asserted-by":"crossref","unstructured":"Furman PA, de Miranda P, St Clair MH et al. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother1981; 20:518\u201324.","DOI":"10.1128\/AAC.20.4.518"},{"key":"key\n\t\t\t\t20171010200240_B7","doi-asserted-by":"crossref","unstructured":"Torre D & Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scandinavian J Infect Dis1999; 31:543\u20137.","DOI":"10.1080\/00365549950164409"},{"key":"key\n\t\t\t\t20171010200240_B8","doi-asserted-by":"crossref","unstructured":"van der Horst C, Joncas J, Ahronheim G et al. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis. J Infect Dis1991; 164:788\u201392.","DOI":"10.1093\/infdis\/164.4.788"},{"key":"key\n\t\t\t\t20171010200240_B9","doi-asserted-by":"crossref","unstructured":"Pagano JS, Sixbey JW, & Lin JC. Acyclovir and Epstein-Barr virus infection. J Antimicrob Chemother1983; 12: Suppl. B, 113\u201321.","DOI":"10.1093\/jac\/12.suppl_B.113"},{"key":"key\n\t\t\t\t20171010200240_B10","doi-asserted-by":"crossref","unstructured":"Purifoy DJ, Beauchamp LM, de Miranda P et al. Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256 U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Medical Virol1993; Suppl. 1: 139\u201345.","DOI":"10.1002\/jmv.1890410527"},{"key":"key\n\t\t\t\t20171010200240_B11","doi-asserted-by":"crossref","unstructured":"Wohl DL, & Isaacson JE. Airway obstruction in children with infectious mononucleosis. Ear Nose Throat J1995; 74:630\u20138.","DOI":"10.1177\/014556139507400909"},{"key":"key\n\t\t\t\t20171010200240_B12","doi-asserted-by":"crossref","unstructured":"Tynell E, Aurelius E, Brandell A et al. Acyclovir and prednisolone treatment of acute infectious mononucleosis: a multicenter, double-blind, placebo-controlled study. J Infect Dis1996; 174:324\u201331.","DOI":"10.1093\/infdis\/174.2.324"},{"key":"key\n\t\t\t\t20171010200240_B13","doi-asserted-by":"crossref","unstructured":"Roy M, Bailey B, Amre DK et al. Dexamethasone for the treatment of sore throat in children with suspected infectious mononucleosis: a randomized, double-blind, placebo-controlled, clinical trial. Archiv Pediatric Adolescent Med2004; 158:250\u20134.","DOI":"10.1001\/archpedi.158.3.250"},{"key":"key\n\t\t\t\t20171010200240_B14","doi-asserted-by":"crossref","unstructured":"Jung D & Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol1999; 39:800\u20134.","DOI":"10.1177\/00912709922008452"},{"key":"key\n\t\t\t\t20171010200240_B15","doi-asserted-by":"crossref","unstructured":"Vere Hodge RA, Sutton D, Boyd MR et al. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob Agents Chemother1989; 33:1765\u201373.","DOI":"10.1128\/AAC.33.10.1765"},{"key":"key\n\t\t\t\t20171010200240_B16","doi-asserted-by":"crossref","unstructured":"Snoeck R, Sakuma T, De Clercq E et al. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother1988; 32:1839\u201344.","DOI":"10.1128\/AAC.32.12.1839"},{"key":"key\n\t\t\t\t20171010200240_B17","doi-asserted-by":"crossref","unstructured":"De Clercq E, Holy A & Rosenberg I. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother1989; 33:185\u201391.","DOI":"10.1128\/AAC.33.2.185"},{"key":"key\n\t\t\t\t20171010200240_B18","doi-asserted-by":"crossref","unstructured":"Datta AK & Hood RE. Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid. Virology1981; 114:52\u20139.","DOI":"10.1016\/0042-6822(81)90251-8"},{"key":"key\n\t\t\t\t20171010200240_B19","doi-asserted-by":"crossref","unstructured":"Yajima Y, Tanaka A & Nonoyama M. Inhibition of productive replication of Epstein-Barr virus DNA by phosphonoacetic acid. Virology1976; 71:352\u20134.","DOI":"10.1016\/0042-6822(76)90119-7"},{"key":"key\n\t\t\t\t20171010200240_B20","doi-asserted-by":"crossref","unstructured":"Brideau RJ, Knechtel ML, Huang A et al. Broad-spectrum antiviral activity of PNU-183792, a 4-oxo-dihydroquinoline, against human and animal herpesviruses. Antiviral Res2002; 54:19\u201328.","DOI":"10.1016\/S0166-3542(01)00208-X"},{"key":"key\n\t\t\t\t20171010200240_B21","doi-asserted-by":"crossref","unstructured":"Oien NL, Brideau RJ, Hopkins TA et al. Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrob Agents Chemother2002; 46:724\u201330.","DOI":"10.1128\/AAC.46.3.724-730.2002"},{"key":"key\n\t\t\t\t20171010200240_B22","doi-asserted-by":"crossref","unstructured":"Townsend LB, Gudmundsson KS, Daluge SM et al. Studies designed to increase the stability and antiviral activity (HCMV) of the active benzimidazole nucleoside, TCRB. Nucleosides Nucleotides1999; 18:509\u201319.","DOI":"10.1080\/15257779908041486"},{"key":"key\n\t\t\t\t20171010200240_B23","doi-asserted-by":"crossref","unstructured":"Kira T, Grill SP, Dutschman GE et al. Anti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinase. Antimicrob Agents Chemother2000; 44:3278\u201384.","DOI":"10.1128\/AAC.44.12.3278-3284.2000"},{"key":"key\n\t\t\t\t20171010200240_B24","doi-asserted-by":"crossref","unstructured":"Zimmermann A, Wilts H, Lenhardt M et al. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res2000; 48:49\u201360.","DOI":"10.1016\/S0166-3542(00)00118-2"},{"key":"key\n\t\t\t\t20171010200240_B25","doi-asserted-by":"crossref","unstructured":"Marschall M, Stein-Gerlach M, Freitag M et al. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J Gen Virol2002; 83:1013\u201323.","DOI":"10.1099\/0022-1317-83-5-1013"},{"key":"key\n\t\t\t\t20171010200240_B26","doi-asserted-by":"crossref","unstructured":"Marschall M, Stein-Gerlach M, Freitag M et al. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J Gen Virol2001; 82:1439\u201350.","DOI":"10.1099\/0022-1317-82-6-1439"},{"key":"key\n\t\t\t\t20171010200240_B27","doi-asserted-by":"crossref","unstructured":"Gershburg E, Hong K & Pagano JS. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob Agents Chemother2004; 48:1900\u20133.","DOI":"10.1128\/AAC.48.5.1900-1903.2004"},{"key":"key\n\t\t\t\t20171010200240_B28","doi-asserted-by":"crossref","unstructured":"De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol2004; 2:704\u201320.","DOI":"10.1038\/nrmicro975"},{"key":"key\n\t\t\t\t20171010200240_B29","doi-asserted-by":"crossref","unstructured":"Moore SM, Cannon JS, Tanhehco YC et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother2001; 45:2082\u20132091.","DOI":"10.1128\/AAC.45.7.2082-2091.2001"},{"key":"key\n\t\t\t\t20171010200240_B30","doi-asserted-by":"crossref","unstructured":"Gustafson EA, Chillemi AC, Sage DR et al. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother1998; 42:2923\u201331.","DOI":"10.1128\/AAC.42.11.2923"},{"key":"key\n\t\t\t\t20171010200240_B31","unstructured":"Pagano JS. Epstein-Barr virus: Therapy of active and latent infection. In: Jeffries DJ, De Clercq E, eds. Antiviral Chemotherapy. John Wiley & Sons Ltd. 1995; pp. 155\u201395."},{"key":"key\n\t\t\t\t20171010200240_B32","doi-asserted-by":"crossref","unstructured":"Townsend LB, Devivar RV, Turk SR et al. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(beta-D-ribofuranosyl)benzimidazoles. J Med Chem1995; 38:4098\u20134105.","DOI":"10.1021\/jm00020a025"},{"key":"key\n\t\t\t\t20171010200240_B33","doi-asserted-by":"crossref","unstructured":"Zacny VL, Gershburg E, Davis MG et al. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol1999; 73:7271\u20137.","DOI":"10.1128\/JVI.73.9.7271-7277.1999"},{"key":"key\n\t\t\t\t20171010200240_B34","doi-asserted-by":"crossref","unstructured":"Underwood MR, Harvey RJ, Stanat SC et al. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J Virol1998; 72:717\u201325.","DOI":"10.1128\/JVI.72.1.717-725.1998"},{"key":"key\n\t\t\t\t20171010200240_B35","doi-asserted-by":"crossref","unstructured":"Krosky PM, Underwood MR, Turk SR et al. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol1998; 72:4721\u20138.","DOI":"10.1128\/JVI.72.6.4721-4728.1998"},{"key":"key\n\t\t\t\t20171010200240_B36","doi-asserted-by":"crossref","unstructured":"Biron KK, Harvey RJ, Chamberlain SC et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother2002; 46:2365\u201372.","DOI":"10.1128\/AAC.46.8.2365-2372.2002"},{"key":"key\n\t\t\t\t20171010200240_B37","doi-asserted-by":"crossref","unstructured":"Koszalka GW, Johnson NW, Good SS et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother2002; 46:2373\u201380.","DOI":"10.1128\/AAC.46.8.2373-2380.2002"},{"key":"key\n\t\t\t\t20171010200240_B38","doi-asserted-by":"crossref","unstructured":"Kern ER, Hartline CB, Rybak RJ et al. Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob Agents Chemother2004; 48:1749\u201355.","DOI":"10.1128\/AAC.48.5.1749-1755.2004"},{"key":"key\n\t\t\t\t20171010200240_B39","doi-asserted-by":"crossref","unstructured":"Krosky PM, Borysko KZ, Nassiri MR et al. Phosphorylation of \u03b2-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus. Antimicrob Agents Chemother2002; 46:478\u201386.","DOI":"10.1128\/AAC.46.2.478-486.2002"},{"key":"key\n\t\t\t\t20171010200240_B40","doi-asserted-by":"crossref","unstructured":"Williams SL, Hartline CB, Kushner NL et al. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother2003; 47:2186\u201392.","DOI":"10.1128\/AAC.47.7.2186-2192.2003"},{"key":"key\n\t\t\t\t20171010200240_B41","doi-asserted-by":"crossref","unstructured":"Gershburg E & Pagano JS. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. J Virol2002; 76:998\u20131003.","DOI":"10.1128\/JVI.76.3.998-1003.2002"},{"key":"key\n\t\t\t\t20171010200240_B42","doi-asserted-by":"crossref","unstructured":"Gershburg E, Marschall M, Hong K et al. Expression and localization of the Epstein-Barr virus-encoded protein kinase. J Virol2004; 78:12140\u20136.","DOI":"10.1128\/JVI.78.22.12140-12146.2004"},{"key":"key\n\t\t\t\t20171010200240_B43","doi-asserted-by":"crossref","unstructured":"Krosky PM, Baek MC, Jahng WJ et al. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol2003; 77:7720\u20137.","DOI":"10.1128\/JVI.77.14.7720-7727.2003"},{"key":"key\n\t\t\t\t20171010200240_B44","doi-asserted-by":"crossref","unstructured":"Krosky PM, Baek MC & Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol2003; 77:905\u201314.","DOI":"10.1128\/JVI.77.2.905-914.2003"},{"key":"key\n\t\t\t\t20171010200240_B45","doi-asserted-by":"crossref","unstructured":"Komazin G, Ptak RG, Emmer BT et al. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol2003; 77:11499\u2013506.","DOI":"10.1128\/JVI.77.21.11499-11506.2003"},{"key":"key\n\t\t\t\t20171010200240_B46","doi-asserted-by":"crossref","unstructured":"Chou S, Marousek GI, Senters AE et al. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol2004; 78:7124\u201330.","DOI":"10.1128\/JVI.78.13.7124-7130.2004"},{"key":"key\n\t\t\t\t20171010200240_B47","doi-asserted-by":"crossref","unstructured":"Wang LH, Peck RW, Yin Y et al. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother2003; 47:1334\u201342.","DOI":"10.1128\/AAC.47.4.1334-1342.2003"},{"key":"key\n\t\t\t\t20171010200240_B48","doi-asserted-by":"crossref","unstructured":"Lalezari JP, Aberg JA, Wang LH et al. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother2002; 46:2969\u201376.","DOI":"10.1128\/AAC.46.9.2969-2976.2002"},{"key":"key\n\t\t\t\t20171010200240_B49","unstructured":"Lu H & Thomas S. Maribavir (ViroPharma). Curr Opin Invest Drugs2004; 5:898\u2013906."},{"key":"key\n\t\t\t\t20171010200240_B50","doi-asserted-by":"crossref","unstructured":"Thomsen DR, Oien NL, Hopkins TA et al. Amino acid changes within conserved region III of the herpes simplex virus and human cytomegalovirus DNA polymerases confer resistance to 4-oxo-dihydroquinolines, a novel class of herpesvirus antiviral agents. J Virol2003; 77:1868\u201376.","DOI":"10.1128\/JVI.77.3.1868-1876.2003"},{"key":"key\n\t\t\t\t20171010200240_B51","doi-asserted-by":"crossref","unstructured":"Hartline CB, Harden EA, Williams-Aziz SL et al. Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res2005; 65:97\u2013105.","DOI":"10.1016\/j.antiviral.2004.10.003"},{"key":"key\n\t\t\t\t20171010200240_B52","doi-asserted-by":"crossref","unstructured":"Pagano JS, Blaser M, Buendia MA et al. Infectious agents and cancer: criteria for a causal relation. Seminars in Cancer Biology2004; 14:453\u201371.","DOI":"10.1016\/j.semcancer.2004.06.009"},{"key":"key\n\t\t\t\t20171010200240_B53","doi-asserted-by":"crossref","unstructured":"Rickinson AB & Kieff E. Epstein-Barr Virus. In: Knipe DM, Howley PM, eds. Fields Virology, 4th edn. Philadelphia: Lippincott-Williams & Wilkins, 2001; pp. 2575\u20132628.","DOI":"10.1016\/S0168-1702(01)00436-1"},{"key":"key\n\t\t\t\t20171010200240_B54","doi-asserted-by":"crossref","unstructured":"Chodosh J, Holder VP, Gan YJ et al. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis1998; 177:1194\u2013201.","DOI":"10.1086\/515290"},{"key":"key\n\t\t\t\t20171010200240_B55","doi-asserted-by":"crossref","unstructured":"Slobod KS, Taylor GH, Sandlund JT et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet2000; 356:1493\u20134.","DOI":"10.1016\/S0140-6736(00)02879-8"},{"key":"key\n\t\t\t\t20171010200240_B56","unstructured":"Gutierrez MI, Judde JG, Magrath IT et al. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res1996; 56:969\u201372."},{"key":"key\n\t\t\t\t20171010200240_B57","unstructured":"Feng WH, Israel B, Raab-Traub N et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res2002; 62:1920\u20136."},{"key":"key\n\t\t\t\t20171010200240_B58","doi-asserted-by":"crossref","unstructured":"Feng WH, Hong G, Delecluse HJ et al. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol2004; 78:1893\u2013902.","DOI":"10.1128\/JVI.78.4.1893-1902.2004"},{"key":"key\n\t\t\t\t20171010200240_B59","doi-asserted-by":"crossref","unstructured":"Mentzer SJ, Fingeroth J, Reilly JJ et al. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells, Molecules Dis1998; 24:114\u201323.","DOI":"10.1006\/bcmd.1998.0178"},{"key":"key\n\t\t\t\t20171010200240_B60","doi-asserted-by":"crossref","unstructured":"Mentzer SJ, Perrine SP & Faller DV. Epstein\u2013Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis2001; 3:177\u201385.","DOI":"10.1034\/j.1399-3062.2001.003003177.x"},{"key":"key\n\t\t\t\t20171010200240_B61","doi-asserted-by":"crossref","unstructured":"Oertel SH & Riess H. Antiviral treatment of Epstein-Barr virus-associated lymphoproliferations. Recent Results Cancer Res2002; 159:89\u201395.","DOI":"10.1007\/978-3-642-56352-2_11"},{"key":"key\n\t\t\t\t20171010200240_B62","doi-asserted-by":"crossref","unstructured":"Faller DV, Mentzer SJ & Perrine SP. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol2001; 13:360\u2013367.","DOI":"10.1097\/00001622-200109000-00008"},{"key":"key\n\t\t\t\t20171010200240_B63","unstructured":"Roychowdhury S, Peng R, Baiocchi RA et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res2003; 63:965\u201371."},{"key":"key\n\t\t\t\t20171010200240_B64","unstructured":"Neyts J, Sadler R, De Clercq E et al. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res1998; 58:384\u20138."},{"key":"key\n\t\t\t\t20171010200240_B65","unstructured":"Murono S, Raab-Traub N & Pagano JS. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res2001; 61:7875\u20137."},{"key":"key\n\t\t\t\t20171010200240_B66","doi-asserted-by":"crossref","unstructured":"Wakisaka N, Yoshizaki T, Murono S et al. Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts. Int J Cancer2005; 116: in press.","DOI":"10.1002\/ijc.21096"},{"key":"key\n\t\t\t\t20171010200240_B67","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Snoeck R, Van Ranst M et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J Med Virol1995; 45:230\u20135.","DOI":"10.1002\/jmv.1890450221"},{"key":"key\n\t\t\t\t20171010200240_B68","unstructured":"Snoeck R, Andrei G & De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg2001; 63: 93\u2013120, discussion 120\u20132."},{"key":"key\n\t\t\t\t20171010200240_B69","doi-asserted-by":"crossref","unstructured":"Abdulkarim B, Sabri S, Zelenika D et al. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene2003; 22:2260\u201371.","DOI":"10.1038\/sj.onc.1206402"},{"key":"key\n\t\t\t\t20171010200240_B70","doi-asserted-by":"crossref","unstructured":"De Clercq E, Andrei G, Balzarini J et al. Antitumor potential of acyclic nucleoside phosphonates. Nucleosides Nucleotides1999; 18:759\u201371.","DOI":"10.1080\/15257779908041563"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/56\/2\/277\/2492801\/dki240.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T01:57:51Z","timestamp":1586311071000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/56\/2\/277\/837426\/EpsteinBarr-virus-infections-prospects-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,8]]},"references-count":70,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,7,8]]},"published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki240","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,8]]},"published":{"date-parts":[[2005,7,8]]}}}